3 ·Filed Apr 30, 2026
Form 3 — initial insider ownership statement
Actionable Insight • Neutral
Routine insider filing with no trading activity or material change. Monitor future Form 4 filings for any open-market purchases or sales by the CEO.
Final — all horizons settled through T+60d ⚠ clustered
COAG ▲ +39.00% at T+60d
NEUTRAL call ✓ call won +39.00% · α vs SPY +35.93% · entry $34.00 → $47.26
T+1d
-25.47%
call -25.47% · α -25.13%
$25.34
settled 5mo ago
T+5d
-26.12%
call -26.12% · α -28.46%
$25.12
settled 5mo ago
T+20d
-20.21%
call -20.21% · α -25.47%
$27.13
settled 4mo ago
T+60d
+39.00%
call +39.00% · α +35.93%
$47.26
settled 2mo ago
Price Chart
Loading chart...
Executive Summary
Benny Sorensen, the President and CEO of Hemab Therapeutics, filed an initial Form 3 disclosing beneficial ownership of warrants to purchase common stock. The filing is a routine initial ownership statement with no material financial impact.
Key Facts
- Benny Sorensen is President and CEO of Hemab Therapeutics Holdings, Inc.
- Form 3 filed on April 30, 2026, as an initial statement of beneficial ownership.
- Sorensen holds four tranches of warrants to buy common stock at exercise prices of $6.08, $2.16, $7.07, and $6.00.
- Warrants expire between 2031 and 2036 and are fully vested or vesting over time.
- No direct ownership of common stock is reported.
Financial Impact
No financial impact; administrative filing of insider ownership.
Risk Factors
- No material risks identified from this filing.
Investment Themes
Biotech & Drug Discovery
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (Primary) | 0001193125-26-198176 |
| Document: 0001193125-26-198176-index-headers.html | 0001193125-26-198176 |
| Document: 0001193125-26-198176-index.html | 0001193125-26-198176 |
| Document: 0001193125-26-198176.txt | 0001193125-26-198176 |
13 reports for COAG
Track record builds as more directional reports settle.
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 7w ago | 8-K | $49.87 $44.50 | ▼ −10.77% | ▼ −9.71% | $30.36 (−39.12%) |
Jun 17, 2026 15w ago | Insider Buy | $29.24 $44.53 | ▲ +52.29% | ▲ +51.76% | $30.36 (+3.83%) |
May 21, 2026 19w ago | Press Release | $26.30 $31.83 | ▲ +21.03% | ▲ +20.69% | $30.36 (+15.44%) |
May 4, 2026 21w ago | 8-K | $25.00 $27.47 | ▲ +9.88% | ▲ +4.93% | $30.36 (+21.44%) |
Apr 30, 2026 22w ago | Press Release | $34.00 $27.13 | ▼ −20.21% | ▼ −25.47% | $30.36 (−10.71%) |
Apr 30, 2026 22w ago | 3 | $34.00 $27.13 | ▼ −20.21% | ▼ −25.47% | $30.36 (−10.71%) |
Apr 30, 2026 22w ago | 3 | $34.00 $27.13 | ▼ −20.21% | ▼ −25.47% | $30.36 (−10.71%) |
Apr 30, 2026 22w ago | 3 | $34.00 $27.13 | ▼ −20.21% | ▼ −25.47% | $30.36 (−10.71%) |
Apr 30, 2026 22w ago | 3 | $34.00 $27.13 | ▼ −20.21% | ▼ −25.47% | $30.36 (−10.71%) |
Apr 30, 2026 22w ago | 3 | $34.00 $27.13 | ▼ −20.21% | ▼ −25.47% | $30.36 (−10.71%) |
Showing 10 of 13
US Market Status
Market Open — Closes in 3h 56m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access